Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
Omeros Corporation reported its first commercial quarter for YARTEMLEA, generating $28.5 million in product sales for the quarter and $38.4 million for the first half of 2026, compared with no product sales in 2025. Net income for the quarter was $13.2 million and for the first six months $69.3 million, versus net losses of $25.4 million and $58.9 million in the prior‑year periods, helped by a $84.6 million net gain on changes in fair value of financial instruments and income from discontinued OMIDRIA royalties.
Cash and cash equivalents were $2.0 million with $130.0 million in short‑term investments as of June 30, 2026. Net cash used in operating activities was $10.4 million for the first half. The OMIDRIA contract royalty asset totaled $116.5 million, offset by an OMIDRIA royalty obligation of $157.9 million. Omeros repurchased portions of its 2029 convertible notes, leaving $54.8 million principal outstanding, and shareholders’ deficit narrowed to $51.3 million from $121.2 million at year‑end 2025.
Omeros Corporation reported strong second-quarter 2026 results driven by the U.S. launch of YARTEMLEA for TA-TMA. YARTEMLEA generated $32.2 million in gross revenue and $28.5 million in net product sales, a 190% increase in gross revenue from $11.1 million in the first quarter of 2026.
GAAP net income was $13.2 million, or $0.18 per basic share, versus a net loss of $25.4 million a year earlier, aided by an $11.4 million non-cash gain on financial instruments and $6.6 million income from discontinued operations. Non-GAAP adjusted net income was $1.8 million, or $0.02 per share. At June 30, 2026, cash and short-term investments totaled $132.0 million, and operating cash flow was $4.1 million for the quarter. The company repurchased $30.5 million principal of 2029 convertible notes, cutting outstanding principal to $40.3 million, eliminating $8.6 million in future interest and reducing potential dilution from 11.4 million to 6.5 million shares, and also retired 0.8 million common shares for $9.9 million. Omeros disclosed a negative CHMP opinion on its narsoplimab MAA in Europe and has requested re-examination while advancing multiple pipeline programs.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,961,792 shares of Omeros Corp common stock. This position represents 8.2% of the outstanding common shares.
BlackRock reports sole voting power over 5,835,368 shares and sole dispositive power over 5,961,792 shares, with no shared voting or dispositive power. Various underlying clients and funds have economic interests in these shares, but no single person has more than five percent of Omeros’ total outstanding common stock.
Omeros Corporation reported that Chairman, CEO & President Gregory A. Demopulos received a grant of 1,000,000 stock options on July 22, 2026. The options have an exercise price of $9.84 per share, expire on July 22, 2036, and are exercisable into an equal number of common shares.
According to the vesting schedule, one-third of the options vest and become exercisable on August 1, 2027, with the remaining options vesting in 32 equal monthly installments on the first day of each month thereafter. Following this grant, he directly holds stock options for 1,000,000 shares.
Omeros Corp granted VP and General Counsel Peter B. Cancelmo 105,000 stock options for common stock on July 22, 2026. The options have a $9.84 per-share exercise price and expire on July 22, 2036. One-third vests on August 1, 2027, with the remaining shares vesting in 32 equal monthly installments thereafter.
Omeros Corp reported that its VP, Finance & CAO, David J. Borges received a grant of 105,000 stock options for common stock at an exercise price of $9.84 per share, expiring on July 22, 2036. One-third vests on August 1, 2027, with the remainder vesting in 32 equal monthly installments thereafter.
Omeros Corporation reports that on July 20, 2026 it completed the repurchase of approximately $14.5 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 under previously disclosed privately negotiated agreements. The total purchase price, inclusive of accrued and unpaid interest and all other obligations, was approximately $29.0 million. Omeros had previously repurchased $16.0 million principal amount of the same Notes from the same holders. In total, the company has now repurchased and retired $30.5 million aggregate principal amount of these Notes, with approximately $40.3 million principal amount remaining outstanding.
Omeros Corporation is repurchasing a portion of its 9.50% Convertible Senior Notes due 2029 and has agreed to buy more. The company expects to complete the repurchase of $16.0 million aggregate principal amount of Notes on July 6, 2026, for a total purchase price of approximately $31.3 million. After this step, about $54.8 million aggregate principal amount of Notes will remain outstanding.
On July 2, 2026, Omeros also agreed to repurchase additional Notes with an aggregate principal amount of up to approximately $14.5 million for a total purchase price of up to approximately $31.0 million, with pricing tied to an averaging period beginning July 6, 2026. If fully completed, these additional repurchases would leave approximately $40.3 million aggregate principal amount of Notes outstanding, and the company may seek unsecured or limited-collateral debt financing to replace some or all of the cash used.
Omeros Corporation reported the results of its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders of record were entitled to vote 72,168,330 common shares, and 58,010,900 shares were represented in person or by proxy, an 80.04% turnout. The filing lists detailed vote totals for the election of directors, including 20,787,774 shares voted for Thomas J. Cable and 10,531,585 against, and 25,314,641 for Peter A. Demopulos, M.D. and 6,063,216 against. It also provides final for/against/abstain and broker non-vote counts for additional shareholder proposals.
Omeros Corporation director Rajiv Shah received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and expire on June 17, 2036. The award was made under Omeros’ non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The option will fully vest and become exercisable on the day before the company’s 2027 annual shareholder meeting, as long as Shah continues serving as a director through that date. Following this grant, he holds 15,000 stock options directly.